Picture of Synsam AB (publ) logo

SYNSAM — Synsam AB (publ) News Story

0.000.00%
se flag iconLast trade - 00:00
Consumer CyclicalsAdventurousMid CapNeutral

Sweden's Synsam Q2 net sales rise on subscription growth

Sweden's Synsam Q2 net sales rise on subscription growth


Overview

  • Sweden-based optician group's Q2 net sales rose 11.3% yr/yr, organic growth 9.8%

  • Company completed SEK 42 mln share buybacks after quarter-end under existing program


Outlook

  • Company plans to open 2-4 new stores in Q3 2026 in the Nordic region

  • Synsam sees strong potential for further expansion in the Nordic region

  • Company says innovation and subscriptions remain key drivers for future growth


Result Drivers

  • SUBSCRIPTION GROWTH - Net sales from spectacles subscriptions rose 16.6% yr/yr, with total subscription customers increasing to about 931,000

  • ORGANIC GROWTH IN ALL MARKETS - All markets reported positive organic growth, with Sweden and Norway seeing improved margins

  • INNOVATION AND STORE EXPANSION - Growth supported by new product categories such as smart glasses, increased use of EyeView, and eight new store openings


Company press release: ID:nWkr3Xc0fT


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

SEK 2.05 bln

Q2 Net Income

SEK 192 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the miscellaneous specialty retailers peer group is "buy."

  • Wall Street's median 12-month price target for Synsam AB (publ) is SEK80.00, about 42.9% above its August 20 closing price of SEK56.00

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago


Reuters Recommended Reads

  • Aug 19 - Norway's Opera Q2 revenue jumps; full-year outlook lifted

  • Aug 18 - Denmark's Coloplast Q3 revenue up on Chronic Care, Urology growth

  • Aug 19 - Switzerland's DocMorris H1 revenue rises on RX growth, raises 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Synsam AB (publ)

See all news